Camrelizumab combined with cetuximab and chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): 1-year outcomes from the phase II trial.

Authors: Dongmei Ji, Youzhou Sang, Yanan Yang, Guangliang Chen, Xin Liu, Yanjin Guo, Shu Dong, Yulong Wang, Xiayun He, Hongmei Ying, Xueguan Lu, Yu Wang, Chaosu Hu, Qinghai Ji

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.6030

Source: Full article

---

Abstract

6030